EarlyCDT-Lung: An Immunobiomarker Test as an Aid to Early Detection of Lung Cancer

Recent publications have reported the technical and clinical validation of EarlyCDT-Lung, an autoantibody test which detected elevated autoantibodies in 40% of lung cancers at diagnosis. This manuscript reports the results of EarlyCDT-Lung run on four new (postvalidation) data sets. The following four cohorts of patients (n = 574) with newly diagnosed lung cancer were identified: group 1 (n = 122), 100% small cell lung cancer (SCLC); group 2 (n = 249), 97% non-small cell lung cancer (NSCLC); group 3 (n = 122), 100% NSCLC; group 4 (n = 81), 62% NSCLC. Serum samples were obtained after diagnosis, prior to any anticancer treatment. Autoantibody levels were measured against a panel of six tumor-related antigens (p53, NY-ESO-1, CAGE, GBU4–5, Annexin 1, and SOX2) in the EarlyCDT-Lung panel and previously established cutoffs applied. In groups 2, 3, and 4, patients were individually matched by gender, age, and smoking history to a control individual with no history of malignant disease. Assay sensitivity was tested in relation to cancer type and stage, and in the matched normals to demographic variables. The autoantibody panel showed sensitivity/specificity of 57%/n.d (not done) for SCLC in group 1, 34%/87% for NSCLC in group 2, 31% and 84% for NSCLC in group 3, and 35%/89% for NSCLC and 43%/89% for SCLC in group 4. There was no significant difference in positivity of EarlyCDT-Lung and different lung cancer stages. These studies confirm the value of an autoantibody assay, EarlyCDT-Lung, as an aid to detecting lung cancer in patients at high risk of the disease. Cancer Prev Res; 4(7); 1126–34. ©2011 AACR.

[1]  P. Prorok,et al.  Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. , 2011, Journal of the National Cancer Institute.

[2]  Andrea Murray,et al.  Immunobiomarkers in Small Cell Lung Cancer: Potential Early Cancer Signals , 2010, Clinical Cancer Research.

[3]  Beryl Rawson,et al.  Degrees of Freedom , 2010 .

[4]  J. Robertson,et al.  The Presence of Autoantibodies to Tumour-Associated Antigens Can Predate Clinical Diagnosis of Small Cell Lung Cancer , 2010 .

[5]  P. Boyle,et al.  Clinical validation of an autoantibody test for lung cancer , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  J. Robertson,et al.  Technical validation of an autoantibody test for lung cancer , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  E. Apostolakis,et al.  Current role of surgery in small cell lung carcinoma , 2009 .

[8]  A. Nicholson,et al.  The Role of Surgery in the Treatment of Limited Disease Small Cell Lung Cancer: Time to Reevaluate , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  David E. Misek,et al.  Identification of 14-3-3θ as an antigen that induces a humoral response in lung cancer , 2007 .

[10]  A Murray,et al.  Autoantibodies in lung cancer: possibilities for early detection and subsequent cure , 2007, Thorax.

[11]  J. Robertson,et al.  Autoantibodies in breast cancer: their use as an aid to early diagnosis. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  A. Stromberg,et al.  Profiling Tumor-Associated Antibodies for Early Detection of Non-small Cell Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  C. Cheadle,et al.  Autoantibody biomarker opens a new gateway for cancer diagnosis. , 2006, Biochimica et biophysica acta.

[14]  S. Pinder,et al.  Autoantibodies in early breast cancer , 2005 .

[15]  Anne-Marie Sykes,et al.  CT screening for lung cancer: five-year prospective experience. , 2005, Radiology.

[16]  K. Hemminki,et al.  p53 autoantibodies predict subsequent development of cancer , 2005, International journal of cancer.

[17]  Hiroyuki Suzuki,et al.  T Cell–Dependent Antibody Responses against Aberrantly Expressed Cyclin B1 Protein in Patients with Cancer and Premalignant Disease , 2005, Clinical Cancer Research.

[18]  Paul Pinsky,et al.  Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute. , 2004, Chest.

[19]  S. Lam,et al.  Lung cancer screening: a different paradigm. , 2003, American journal of respiratory and critical care medicine.

[20]  B. Stewart,et al.  World Cancer Report , 2003 .

[21]  J. Koziol,et al.  Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  Hajime Nakata,et al.  Lung cancer screening using low-dose spiral CT: results of baseline and 1-year follow-up studies. , 2002, Chest.

[23]  W. Heindel,et al.  Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. , 2002, Radiology.

[24]  Hironobu Ohmatsu,et al.  Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Tan.  Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. , 2001, The Journal of clinical investigation.

[26]  S M Hanash,et al.  An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  O S Miettinen,et al.  Early Lung Cancer Action Project , 2001, Cancer.

[28]  S. Sone,et al.  Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner , 2001, British Journal of Cancer.

[29]  E. Rieber,et al.  Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. , 2000, Cancer research.

[30]  O. Miettinen,et al.  Early Lung Cancer Action Project: overall design and findings from baseline screening , 1999, The Lancet.

[31]  Feng Li,et al.  Mass screening for lung cancer with mobile spiral computed tomography scanner , 1998, The Lancet.

[32]  Sylvia Richardson,et al.  Markov Chain Monte Carlo in Practice , 1997 .

[33]  H. Ohmatsu,et al.  Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. , 1996, Radiology.

[34]  J. Jett,et al.  Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  A. Houghton.  Cancer antigens: immune recognition of self and altered self , 1994, The Journal of experimental medicine.

[36]  J. Robertson,et al.  Failure of CA19-9 to detect asymptomatic colorectal carcinoma. , 1991, British Journal of Cancer.

[37]  A. Neville,et al.  Role of Plasma Carcinoembryonic Antigen in Diagnosis of Gastrointestinal, Mammary, and Bronchial Carcinoma , 1972, British medical journal.

[38]  L. Tanoue,et al.  Cumulative Incidence of False-Positive Test Results in Lung Cancer Screening: A Randomized Trial , 2011 .

[39]  David E. Misek,et al.  Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer. , 2007, Cancer research.

[40]  J. Herman,et al.  Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. , 2005, The Journal of thoracic and cardiovascular surgery.

[41]  A. Howell,et al.  Prospective assessment of the role of five tumour markers in breast cancer , 2005, Cancer Immunology, Immunotherapy.

[42]  Charles J. Geyer,et al.  Estimation and Optimization of Functions , 1996 .

[43]  A. Howell,et al.  Assessment of four monoclonal antibodies as serum markers in breast cancer. , 1990, European journal of cancer.